These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum. Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220 [TBL] [Abstract][Full Text] [Related]
6. [A case report of stage IV cecal cancer exhibiting a complete response to multidisciplinary therapy]. Matsuyama T; Ishikawa T; Masuda T; Okazaki S; Ishiguro M; Kobayashi H; Iida S; Uetake H; Sugihara K Gan To Kagaku Ryoho; 2012 Nov; 39(12):2246-8. PubMed ID: 23268038 [TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES). Janjua TK; Hassan M; Afridi HK; Zahid NA BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978604 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264 [TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774 [TBL] [Abstract][Full Text] [Related]
11. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. Pluschnig U; Schoppmann SF; Preusser M; Datler P; Asari R; Ba-Ssalamah A; Schwameis K; Birner P; Zacherl J; Hejna M Anticancer Res; 2013 Mar; 33(3):1035-9. PubMed ID: 23482778 [TBL] [Abstract][Full Text] [Related]
12. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Dupont J; Jensen HA; Jensen BV; Pfeiffer P Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083 [TBL] [Abstract][Full Text] [Related]
17. Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. Potenza S; Nasti G; Ottaiano A; Filippelli A; Rossi F; Capuano A Invest New Drugs; 2010 Apr; 28(2):185-6. PubMed ID: 19352593 [TBL] [Abstract][Full Text] [Related]
18. Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer. Amini A; Sanati H Anticancer Drugs; 2011 Nov; 22(10):1024-6. PubMed ID: 21822120 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]